ClinicalTrials.Veeva

Menu

Short- and Long Term Growth in Children With Asthma

C

Children´s Clinic, Randers

Status and phase

Completed
Phase 4

Conditions

Asthma

Treatments

Drug: Budesonide
Drug: Montelukast

Study type

Interventional

Funder types

Other

Identifiers

NCT00380484
EudractCT-nr 2006-003013-41
BKR-KNAST-06

Details and patient eligibility

About

The purpose of this study is to assess if treatment with budesonide 200 microgram per day affects short- or long term growth in children with asthma

Full description

When children with asthma are treated with inhaled corticosteroids there is a risk of systemic adverse events such as growth suppression. It has been reported that treatment with budesonide 200 microgram per day does not affect short term growth in children with asthma. The aim of the present study is to assess if an unaffected short term growth means that also long term growth will be unaffected.

Short and long term growth in asthmatic children treated with budesonide will be compared with the growth in asthmatic children treated with montelukast.

Enrollment

52 patients

Sex

All

Ages

6 to 11 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • age 6-11,
  • prepubertal,
  • asthma,
  • normal weight and height,
  • informed consent

Exclusion criteria

  • treatment with systemic/inhaled/intranasal corticosteroids within the last week,
  • major surgery within 4 weeks,
  • usage of drugs that significantly inhibit CYP3A4

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

52 participants in 2 patient groups

1
Experimental group
Description:
Budesonide
Treatment:
Drug: Budesonide
2
Active Comparator group
Description:
Montelukast
Treatment:
Drug: Montelukast

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems